早期子宫内膜癌中β-catenin异常表达与辅助放疗改善局部控制相关
研究纳入213例2009至2021年手术的FIGO 2018 I-II期子宫内膜样癌患者,评估β-catenin表达。中位随访53.2个月,全队列中β-catenin异常表达与阴道复发显著相关(多因素p=0.03)。在NSMP亚组中,接受辅助放疗者阴道复发0%,未接受者20.9%(p=0.03)。
要点
- 全队列中β-catenin异常表达与阴道复发显著相关,多因素分析p=0.03。
- NSMP亚组中β-catenin异常表达者接受放疗阴道复发0%,未接受者20.9%(p=0.03)。
- 作者建议I-II期NSMP子宫内膜癌伴β-catenin异常表达者可考虑辅助放疗以降低阴道复发风险。
核心结论
- 对I-II期NSMP子宫内膜癌伴β-catenin异常表达者使用辅助放疗改善了局部控制,作者建议可考虑放疗以降低阴道复发风险。
研究设计与样本
- 研究识别了213例2009至2021年接受手术的FIGO 2018 I-II期子宫内膜样子宫内膜癌患者,并评估了β-catenin表达。
- 采用竞争风险方法分析阴道、区域和远处复发,采用Kaplan-Meier分析总生存。
主要发现
- 中位随访53.2个月;6.9%发生阴道复发,8.2%发生区域复发,7.4%发生远处复发。
- 全队列中β-catenin异常表达与阴道复发显著相关,多因素分析仍显著(p=0.03)。
- NSMP亚组共114例,β-catenin异常表达者占46.5%;该亚组中β-catenin异常表达与阴道复发率升高相关(p=0.06),多因素分析显著(p=0.04)。
- 全队列中β-catenin异常表达者接受放疗的阴道复发为0%,未接受放疗者为17.5%(p=0.03)。
- NSMP亚组中接受放疗者阴道复发0%,未接受放疗者20.9%(p=0.03)。
临床怎么用
- 作者认为,对I-II期NSMP子宫内膜癌伴β-catenin异常表达者,可考虑辅助放疗以降低阴道复发风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Emerging data suggests that abnormal (nuclear) β-catenin expression in some settings is associated with poorer outcomes. Our study aimed to verify the significance of abnormal β-catenin expression in early-stage endometrial cancer patients and determine if adjuvant radiation therapy (RT) improves local control. METHODS: We identified 213 patients with FIGO 2018 stage I-II endometrioid endometrial cancer who underwent surgery from 2009 to 2021 with β-catenin expression assessed. Vaginal, regional, and distant recurrences were analyzed using competing risk methods, and overall survival was analyzed using Kaplan-Meier. RESULTS: Median follow up was 53.2 months; 6.9% experienced vaginal, 8.2% regional, and 7.4% distant recurrence. For the entire cohort, abnormal β-catenin expression was significantly associated with vaginal recurrence and remained significant on multivariate analysis (p = 0.03). There were 114 patients in the no specific molecular profile (NSMP) subgroup, and abnormal β-catenin expression was present in 46.5%. In the NSMP subgroup, abnormal β-catenin expression was associated with increased rates of vaginal recurrence (p = 0.06). Abnormal β-catenin expression in the NSMP subgroup was significant on multivariate analysis for vaginal recurrence (p = 0.04). RT significantly decreased vaginal recurrences in the entire cohort in patients with abnormal β-catenin expression (0%) versus wild type expression (17.5%; p = 0.03). In the NSMP subgroup 0% of patients who received RT versus 20.9% of patients who did not receive RT experienced a vaginal recurrence (p = 0.03). CONCLUSION: Use of adjuvant RT for stage I-II NSMP endometrial cancer with abnormal β-catenin expression improved local control. RT should be considered in these patients to decrease risk of vaginal recurrences.
引用
- Hui C, Mendoza MG, Snyder J, et al. Adjuvant radiation therapy in early-stage endometrial cancer with abnormal beta-catenin expression is associated with improved local control. Gynecol Oncol. 2023. PMID: 37149904. doi:10.1016/j.ygyno.2023.04.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。